The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas

被引:32
|
作者
Pham, Lan V. [1 ]
Pogue, Elizabeth [1 ]
Ford, Richard J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源
FRONTIERS IN ONCOLOGY | 2018年 / 8卷
关键词
B-cell lymphoma; lymphoma-associated macrophages; tumor microenvironment; immune suppression mechanism; macrophages; TUMOR-ASSOCIATED MACROPHAGES; NURSE-LIKE CELLS; IMMUNE-CHECKPOINT BLOCKADE; FOLLICULAR LYMPHOMA; MONOCYTE COUNT; PROGNOSTIC IMPACT; BONE-MARROW; STARRY SKY; LYMPHOCYTE/MONOCYTE RATIO; MOLECULAR PATHOGENESIS;
D O I
10.3389/fonc.2018.00147
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Macrophages (MPs) are heterogeneous, multifunctional, myeloid-derived leukocytes that are part of the innate immune system, playing wide-ranging critical roles in basic biological activities, including maintenance of tissue homeostasis involving clearance of microbial pathogens. Tumor-associated MPs (TAMs) are MPs with defined specific M2 phenotypes now known to play central roles in the pathophysiology of a wide spectrum of malignant neoplasms. Also, TAMs are often intrinsic cellular components of the essential tumor microenvironment (TME). In concert with lymphoid-lineage B and T cells at various developmental stages, TAMs can mediate enhanced tumor progression, often leading to poor clinical prognosis, at least partly through secretion of chemokines, cytokines, and various active proteases shown to stimulate tumor growth, angiogenesis, metastasis, and immunosuppression. Researchers recently showed that TAMs express certain key checkpoint-associated proteins [e.g., programmed cell death protein 1 (PD-1), programmed cell death-ligand 1 (PD-L1)] that appear to be involved in T-cell activation and that these proteins are targets of other specific checkpoint-blocking immunotherapies (anti-PD-1/PD-L1) currently part of new therapeutic paradigms for chemotherapy-resistant neoplasms. Although much is known about the wide spectrum and flexibility of MPs under many normal and neoplastic conditions, relatively little is known about the increasingly important interactions between MPs and B-lymphoid cells, particularly in the TME in patients with aggressive B-cell non-Hodgkin lymphoma (NHL-B). Normal and neoplastic lymphoid and myeloid cell/MP lineages appear to share many primitive cellular characteristics as well as transcriptional factor interactions in human and animal ontogenic studies. Such cells are capable of ectopic transcription factor-induced lineage reprogramming or transdifferentiation from early myeloid/monocytic lineages to later induce B-cell lymphomagenesis in experimental in vivo murine systems. Close cellular interactions between endogenous clonal neoplastic B cells and related aberrant myeloid precursor cells/MPs appear to be important interactive components of aggressive NHL-B that we discuss herein in the larger context of the putative role of B-cell/MP cellular lineage interactions involved in NHL-B pathophysiology during ensuing lymphoma development.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] THE ROLE OF IDIOTYPIC INTERACTIONS AND B-CELL SUBSETS IN DEVELOPMENT OF THE B-CELL REPERTOIRE
    KEARNEY, JF
    VAKIL, M
    SOLVASON, N
    [J]. COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1989, 54 : 203 - 207
  • [2] THE ROLE OF IDIOTYPIC INTERACTIONS AND B-CELL SUBSETS IN DEVELOPMENT OF THE B-CELL REPERTOIRE
    KEARNEY, JF
    VAKIL, M
    SOLVASON, N
    [J]. IMMUNOLOGICAL RECOGNITION, PTS 1 AND 2, 1989, 54 : 203 - 207
  • [3] Expression of B-cell markers in different indolent B-cell lymphomas
    Khoudoleeva, O. A.
    Vorobjev, I. A.
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2012, 82B (04) : O11 - O12
  • [4] Aggressive B-cell lymphomas
    Yang, W
    Listinsky, CM
    [J]. UPDATES IN DIAGNOSTIC PATHOLOGY, 2005, 563 : 125 - 134
  • [5] MONOCYTOID B-CELL LYMPHOMAS
    ISAACSON, PG
    SPENCER, J
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1990, 14 (09) : 888 - 890
  • [6] Immunotherapy in the B-cell lymphomas
    Gribben, JG
    [J]. CYTOTHERAPY, 2002, 4 (05) : 439 - 440
  • [7] Zandelisib and B-Cell Lymphomas
    O'Brien, Susan
    Zelenetz, Andrew D.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (03) : 117 - 119
  • [8] Cutaneous B-Cell Lymphomas
    Villasenor-Park, Jennifer
    Chung, Jina
    Kim, Ellen J.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (05) : 1111 - 1131
  • [9] Ibrutinib in B-cell Lymphomas
    Maddocks, Kami
    Blum, Kristie A.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (02) : 226 - 237
  • [10] B-cell epidermotropism in lymphomas
    Kerl, H
    [J]. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 1999, 21 (01) : 110 - 110